-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
•
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen Inc. (NASDAQ: SGEN), with the deal set to close today. The US pharmaceutical giant had to make concessions to address the US Federal Trade Commission’s (FTC) concerns over…
-
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
•
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has released the results of a Phase II study combining its antibody drug conjugate (ADC) Adcetris (brentuximab vedotin) with Merck, Sharp & Dohme’s (MSD; NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab). The study focused on patients with…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
